Compstatin Analog Sustained Release for Respiratory Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors have limitations in effectively targeting local complement activation in inflammatory conditions of the respiratory system, as systemic administration faces challenges in achieving effective concentrations and is often impractical for chronic conditions, and local administration may not adequately address extravascular complement activation.
Innovation Solution
A compstatin analog with a cyclic peptide core sequence of X'aa—Gln—Asp—Xaa—Gly, where X'aa and Xaa are Trp or its analogs, is administered directly to the respiratory tract in a sustained release formulation to inhibit local complement activation, specifically targeting C3, factor B, or factor D, and can be combined with other therapeutic agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of complement inhibitors is used, then complement activation is inhibited throughout the body, but achieving effective concentrations at local sites is difficult and systemic effects cause unwanted side effects
Solution Approach 1:
The patent applies local quality by designing complement inhibitors with properties that enable selective accumulation at local sites of complement activation (such as inflamed respiratory tissues) rather than uniform distribution throughout the body. The inhibitors are formulated to have enhanced local concentration at target sites while minimizing systemic exposure, thereby achieving effective local complement inhibition without widespread systemic side effects.
2Object-affected harmful factors
If local administration of complement inhibitors is used, then local complement activation is targeted, but extravascular complement activation may not be adequately addressed
Solution Approach 1:
The patent applies universality by designing complement inhibitors that can function effectively at multiple locations and levels of complement activation. The inhibitors are formulated to address both local extravascular complement activation at tissue sites and systemic complement activation in the vasculature, providing comprehensive coverage through a single agent that operates effectively in multiple compartments of the body.
3Duration of action of moving object
If chronic administration of complement inhibitors is used, then sustained therapeutic effect is achieved, but long-term safety and practicality are compromised
Solution Approach 1:
The patent applies continuity of useful action by designing complement inhibitors with extended half-lives and sustained release formulations that maintain therapeutic concentrations over prolonged periods. The inhibitors are formulated to provide continuous complement inhibition without requiring frequent dosing, thereby achieving long-term therapeutic effect while improving practicality and reducing the need for chronic monitoring and adjustment.
Data Source
Figure 1
AI summary
The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.